{"id":25510,"date":"2025-01-11T12:41:49","date_gmt":"2025-01-11T11:41:49","guid":{"rendered":"https:\/\/tirzepatyd.eu\/?post_type=product&#038;p=25510"},"modified":"2026-04-18T10:15:50","modified_gmt":"2026-04-18T08:15:50","slug":"tirzepatid-20mg","status":"publish","type":"product","link":"https:\/\/tirzepatyd.eu\/en\/product\/tirzepatid-20mg\/","title":{"rendered":"GLP1+GIP 20 mg"},"content":{"rendered":"<div data-elementor-type=\"product-post\" data-elementor-id=\"25510\" class=\"elementor elementor-25510\" data-elementor-post-type=\"product\">\n\t\t\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-0a060c4 elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"0a060c4\" data-element_type=\"section\" data-e-type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-10a03f2\" data-id=\"10a03f2\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-8d55ed4 elementor-widget elementor-widget-text-editor\" data-id=\"8d55ed4\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<h2 data-start=\"215\" data-end=\"285\">Tirzepatide 20mg - molecular characterization<\/h2><p data-start=\"287\" data-end=\"654\"><span class=\"hover:entity-accent entity-underline inline cursor-pointer align-baseline\"><span class=\"whitespace-normal\">Thirzepatide 20mg<\/span><\/span>\u00a0is a synthetic peptide with a molecular weight of approximately 4813 Da, designed as a dual agonist for GIPR and GLP-1R receptors. The molecule contains a modified amino acid sequence and a lipid chain that allows reversible binding to albumin, which prolongs the half-life and increases stability in the biological environment.<\/p><p data-start=\"656\" data-end=\"924\">According to pharmacological analyses described in a review by Min et al. (2023), tirzepatide shows the ability to activate incretin receptors through a Gs protein-dependent mechanism, leading to an increase in cAMP levels and activation of downstream signaling cascades.<\/p><hr data-start=\"926\" data-end=\"929\" \/><h2 data-start=\"931\" data-end=\"1000\">Thiothrombate 20mg receptor mechanism - data from preclinical and clinical studies<\/h2><p data-start=\"1002\" data-end=\"1047\">Dual activation of GIPR and GLP-1R leads to:<\/p><ul data-start=\"1049\" data-end=\"1253\"><li data-start=\"1049\" data-end=\"1095\"><p data-start=\"1051\" data-end=\"1095\">An increase in glucose-dependent insulin secretion,<\/p><\/li><li data-start=\"1096\" data-end=\"1160\"><p data-start=\"1098\" data-end=\"1160\">Inhibition of glucagon secretion under hyperglycemic conditions,<\/p><\/li><li data-start=\"1161\" data-end=\"1198\"><p data-start=\"1163\" data-end=\"1198\">Slowing gastric emptying,<\/p><\/li><li data-start=\"1199\" data-end=\"1253\"><p data-start=\"1201\" data-end=\"1253\">Effects on central mechanisms regulating appetite.<\/p><\/li><\/ul><p data-start=\"1255\" data-end=\"1410\">In vitro studies have shown that activation of these receptors increases cAMP levels and modulates the expression of genes related to glucose and lipid metabolism.<\/p><p data-start=\"1412\" data-end=\"1607\">A mechanistic review (Min T. et al., 2023) emphasizes that simultaneous activation of GIP and GLP-1 can lead to a synergistic effect beyond the sum of the effects of the individual agonists.<\/p><p data-start=\"1609\" data-end=\"1669\">Source:<br data-start=\"1616\" data-end=\"1619\" \/><a class=\"decorated-link\" href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC10107501\/\" target=\"_new\" rel=\"noopener\" data-start=\"1619\" data-end=\"1669\">https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC10107501\/<\/a><\/p><hr data-start=\"1671\" data-end=\"1674\" \/><h2 data-start=\"1676\" data-end=\"1744\">Results of clinical trials - analysis of highest exposure levels<\/h2><p data-start=\"1746\" data-end=\"1897\">In the SURMOUNT-1 study published in the <span class=\"hover:entity-accent entity-underline inline cursor-pointer align-baseline\"><span class=\"whitespace-normal\">New England Journal of Medicine<\/span><\/span> (2022) evaluated the effect of tirzepatydu on body weight at 72-week follow-up.<\/p><p data-start=\"1899\" data-end=\"1963\">For the highest dose analyzed in the study (15 mg), they reported:<\/p><ul data-start=\"1965\" data-end=\"2127\"><li data-start=\"1965\" data-end=\"2003\"><p data-start=\"1967\" data-end=\"2003\">average weight reduction of 20.9%,<\/p><\/li><li data-start=\"2004\" data-end=\"2057\"><p data-start=\"2006\" data-end=\"2057\">\u226520% weight reduction in more than 50% participants,<\/p><\/li><li data-start=\"2058\" data-end=\"2127\"><p data-start=\"2060\" data-end=\"2127\">improving lipid parameters and lowering systolic blood pressure.<\/p><\/li><\/ul><p data-start=\"2129\" data-end=\"2306\">In SURPASS-2 (NEJM 2021), it was shown that tirzepatide led to greater reductions in HbA1c than <span class=\"hover:entity-accent entity-underline inline cursor-pointer align-baseline\"><span class=\"whitespace-normal\">Semaglutide<\/span><\/span> And to a significant reduction in body weight.<\/p><p data-start=\"2308\" data-end=\"2403\">Sources:<br data-start=\"2315\" data-end=\"2318\" \/><a class=\"decorated-link\" href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/35658024\/\" target=\"_new\" rel=\"noopener\" data-start=\"2318\" data-end=\"2359\">https:\/\/pubmed.ncbi.nlm.nih.gov\/35658024\/<\/a><br data-start=\"2359\" data-end=\"2362\" \/><a class=\"decorated-link\" href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/34170647\/\" target=\"_new\" rel=\"noopener\" data-start=\"2362\" data-end=\"2403\">https:\/\/pubmed.ncbi.nlm.nih.gov\/34170647\/<\/a><\/p><p data-start=\"2405\" data-end=\"2495\">These data indicate a clear dose-dependent effect and intensity of receptor activation.<\/p><hr data-start=\"2497\" data-end=\"2500\" \/><h2 data-start=\"2502\" data-end=\"2537\">Research significance of the tirzepatid 20mg variant<\/h2><p data-start=\"2539\" data-end=\"2676\">Although registration studies have analyzed doses up to 15 mg, the 20 mg variant provides a model in the laboratory setting for evaluation:<\/p><ul data-start=\"2678\" data-end=\"2861\"><li data-start=\"2678\" data-end=\"2729\"><p data-start=\"2680\" data-end=\"2729\">maximum activation of incretin receptors,<\/p><\/li><li data-start=\"2730\" data-end=\"2761\"><p data-start=\"2732\" data-end=\"2761\">dose-response relationships,<\/p><\/li><li data-start=\"2762\" data-end=\"2798\"><p data-start=\"2764\" data-end=\"2798\">GPCR signaling intensity,<\/p><\/li><li data-start=\"2799\" data-end=\"2861\"><p data-start=\"2801\" data-end=\"2861\">metabolic effects at higher receptor exposure.<\/p><\/li><\/ul><p data-start=\"2863\" data-end=\"3023\">In animal models, activation of the GIP\/GLP-1 axis led to changes in the expression of genes related to lipid metabolism and regulation of carbohydrate metabolism.<\/p><hr data-start=\"3025\" data-end=\"3028\" \/><h2 data-start=\"3030\" data-end=\"3060\">The nature and quality of the material<\/h2><p data-start=\"3062\" data-end=\"3192\">Tirzepatide 20 mg offered as test material is a reference substance for biochemical and pharmacological analyses.<\/p><p data-start=\"3194\" data-end=\"3357\">Product quality should be confirmed by analytical documentation (e.g., HPLC profile, certificate of analysis - CoA), ensuring reproducibility of experimental results.<\/p><p data-start=\"3359\" data-end=\"3451\">The product is intended for research and analytical use only (Research Use Only).<\/p><hr data-start=\"3025\" data-end=\"3028\" \/><h2 data-start=\"127\" data-end=\"195\">Thirzepatide vs Semaglutide vs Retatrutide - receptor mechanism<\/h2><p data-start=\"197\" data-end=\"450\"><span class=\"hover:entity-accent entity-underline inline cursor-pointer align-baseline\"><span class=\"whitespace-normal\">Semaglutide<\/span><\/span>, <span class=\"hover:entity-accent entity-underline inline cursor-pointer align-baseline\"><span class=\"whitespace-normal\">Tirzepatide<\/span><\/span> and <span class=\"hover:entity-accent entity-underline inline cursor-pointer align-baseline\"><span class=\"whitespace-normal\">Retatrutide<\/span><\/span> belong to a group of advanced incretin agonists that differ in the extent of receptor activation and pharmacodynamic profile.<\/p><p data-start=\"452\" data-end=\"661\"><strong data-start=\"452\" data-end=\"467\">Semaglutide<\/strong> acts selectively on the GLP-1R receptor. Activation of this receptor leads to an increase in cAMP levels, modulation of the insulinotropic response and effects on central mechanisms regulating appetite.<\/p><p data-start=\"663\" data-end=\"1138\"><strong data-start=\"663\" data-end=\"678\">Tirzepatide<\/strong>, including a variant referred to as <strong data-start=\"709\" data-end=\"728\">tirzepatid 20mg<\/strong>, exhibits a dual mechanism of action through simultaneous activation of GLP-1R and GIPR receptors. Integration of these two incretin axes leads to the enhanced cAMP-dependent response and pronounced dose-dependent effect observed in clinical trials. The literature indicates that dual GIP + GLP-1 agonism can generate a synergistic effect beyond that of a selective GLP-1 agonist.<\/p><p data-start=\"1140\" data-end=\"1400\"><strong data-start=\"1140\" data-end=\"1155\">Retatrutide<\/strong> represents a more complex model - it activates GLP-1R, GIPR and glucagon receptor (GCGR). Such triagonism expands the metabolic response to include additional mechanisms related to the regulation of lipid and energy substrate metabolism.<\/p><p data-start=\"1402\" data-end=\"1431\">To summarize mechanistically:<\/p><ul data-start=\"1433\" data-end=\"1596\"><li data-start=\"1433\" data-end=\"1478\"><p data-start=\"1435\" data-end=\"1478\">semaglutide - a selective GLP-1R agonist,<\/p><\/li><li data-start=\"1479\" data-end=\"1547\"><p data-start=\"1481\" data-end=\"1547\">tirzepatide \/ tirzepatid 20mg - dual agonist of GLP-1R and GIPR,<\/p><\/li><li data-start=\"1548\" data-end=\"1596\"><p data-start=\"1550\" data-end=\"1596\">retatrutide - a triagonist of GLP-1R, GIPR and GCGR.<\/p><\/li><\/ul><p data-start=\"1598\" data-end=\"1710\">The range of activated receptors is a key element in differentiating these molecules in pharmacological studies.<\/p><hr data-start=\"1712\" data-end=\"1715\" \/><h2 data-start=\"1717\" data-end=\"1783\">Thirzepatide 20mg - availability and where to buy (research nature)<\/h2><p data-start=\"1785\" data-end=\"1942\">In a laboratory context <strong data-start=\"1813\" data-end=\"1832\">tirzepatid 20mg<\/strong> functions as a reference material for research use only (Research Use Only).<\/p><p data-start=\"1944\" data-end=\"2071\">Substances of this type are offered by specialized suppliers of reagents and analytical materials that provide:<\/p><ul data-start=\"2073\" data-end=\"2226\"><li data-start=\"2073\" data-end=\"2128\"><p data-start=\"2075\" data-end=\"2128\">Quality documentation (Certificate of Analysis - CoA),<\/p><\/li><li data-start=\"2129\" data-end=\"2174\"><p data-start=\"2131\" data-end=\"2174\">A confirmed purity profile (e.g., HPLC),<\/p><\/li><li data-start=\"2175\" data-end=\"2226\"><p data-start=\"2177\" data-end=\"2226\">Batch identification and storage conditions.<\/p><\/li><\/ul><p data-start=\"2228\" data-end=\"2344\">In research marketing, it is important to confirm the analytical quality and compatibility with the experimental purpose.<\/p><p data-start=\"2346\" data-end=\"2464\">The product is not intended for stand-alone therapeutic use or for use outside controlled trials.<\/p><p data-start=\"2346\" data-end=\"2464\"><a href=\"https:\/\/tirzepatyd.eu\/de\/shop-produkt\/tirzepatide-20-mg-stift\">See also Tirzepatide 20 mg in device (Pen)<\/a><\/p><hr data-start=\"1712\" data-end=\"1715\" \/><p data-start=\"2346\" data-end=\"2464\"><a href=\"https:\/\/tirzepatyd.eu\/wp-content\/uploads\/2026\/02\/Tirzepatid-20mg.png\"><img fetchpriority=\"high\" decoding=\"async\" class=\"wp-image-35032 size-medium aligncenter\" src=\"https:\/\/tirzepatyd.eu\/wp-content\/uploads\/2026\/02\/Tirzepatid-20mg-300x225.png\" alt=\"Tirzepatid 20mg in vial \u2013 high purity laboratory peptide\" width=\"300\" height=\"225\" srcset=\"https:\/\/tirzepatyd.eu\/wp-content\/uploads\/2026\/02\/Tirzepatid-20mg-300x225.png 300w, https:\/\/tirzepatyd.eu\/wp-content\/uploads\/2026\/02\/Tirzepatid-20mg-768x576.png 768w, https:\/\/tirzepatyd.eu\/wp-content\/uploads\/2026\/02\/Tirzepatid-20mg-16x12.png 16w, https:\/\/tirzepatyd.eu\/wp-content\/uploads\/2026\/02\/Tirzepatid-20mg-800x600.png 800w, https:\/\/tirzepatyd.eu\/wp-content\/uploads\/2026\/02\/Tirzepatid-20mg-400x300.png 400w, https:\/\/tirzepatyd.eu\/wp-content\/uploads\/2026\/02\/Tirzepatid-20mg-64x48.png 64w, https:\/\/tirzepatyd.eu\/wp-content\/uploads\/2026\/02\/Tirzepatid-20mg.png 1024w\" sizes=\"(max-width: 300px) 100vw, 300px\" \/><\/a><\/p><hr data-start=\"1712\" data-end=\"1715\" \/><p data-start=\"2346\" data-end=\"2464\"><strong>Product intended for scientific research and laboratory analysis. All articles and information on this site are for informational and educational purposes only.<\/strong><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<\/div>","protected":false},"excerpt":{"rendered":"<p data-start=\"115\" data-end=\"438\"><strong data-start=\"115\" data-end=\"134\">Thirzepatide 20mg vial<\/strong> is an advanced synthetic peptide with dual activity against GIP and GLP-1 receptors, used in specialized studies of incretin metabolism and signaling. The 20 mg variant enables analysis of intense receptor activation and dose-effect relationships under laboratory conditions.<\/p>","protected":false},"featured_media":25514,"comment_status":"open","ping_status":"closed","template":"","meta":{"_acf_changed":false},"product_brand":[],"product_cat":[124,111,15],"product_tag":[136],"class_list":{"0":"post-25510","1":"product","2":"type-product","3":"status-publish","4":"has-post-thumbnail","6":"product_cat-produkty-w-fiolce","7":"product_cat-glp1gip","8":"product_cat-laboratory-research","9":"product_tag-fiolka","11":"first","12":"instock","13":"shipping-taxable","14":"purchasable","15":"product-type-simple"},"acf":[],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/tirzepatyd.eu\/en\/wp-json\/wp\/v2\/product\/25510","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/tirzepatyd.eu\/en\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/tirzepatyd.eu\/en\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/tirzepatyd.eu\/en\/wp-json\/wp\/v2\/comments?post=25510"}],"version-history":[{"count":15,"href":"https:\/\/tirzepatyd.eu\/en\/wp-json\/wp\/v2\/product\/25510\/revisions"}],"predecessor-version":[{"id":35456,"href":"https:\/\/tirzepatyd.eu\/en\/wp-json\/wp\/v2\/product\/25510\/revisions\/35456"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/tirzepatyd.eu\/en\/wp-json\/wp\/v2\/media\/25514"}],"wp:attachment":[{"href":"https:\/\/tirzepatyd.eu\/en\/wp-json\/wp\/v2\/media?parent=25510"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/tirzepatyd.eu\/en\/wp-json\/wp\/v2\/product_brand?post=25510"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/tirzepatyd.eu\/en\/wp-json\/wp\/v2\/product_cat?post=25510"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/tirzepatyd.eu\/en\/wp-json\/wp\/v2\/product_tag?post=25510"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}